DK3491139T3 - Lentivirusvektorer til ekspression af hepatitis b virus- (hbv-) -antigener - Google Patents
Lentivirusvektorer til ekspression af hepatitis b virus- (hbv-) -antigener Download PDFInfo
- Publication number
- DK3491139T3 DK3491139T3 DK17749145.3T DK17749145T DK3491139T3 DK 3491139 T3 DK3491139 T3 DK 3491139T3 DK 17749145 T DK17749145 T DK 17749145T DK 3491139 T3 DK3491139 T3 DK 3491139T3
- Authority
- DK
- Denmark
- Prior art keywords
- antigenes
- hbv
- virus
- lentivirus vectors
- expressing hepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305976.9A EP3276006A1 (en) | 2016-07-27 | 2016-07-27 | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens |
| PCT/EP2017/068412 WO2018019705A1 (en) | 2016-07-27 | 2017-07-20 | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3491139T3 true DK3491139T3 (da) | 2022-06-27 |
Family
ID=56939982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17749145.3T DK3491139T3 (da) | 2016-07-27 | 2017-07-20 | Lentivirusvektorer til ekspression af hepatitis b virus- (hbv-) -antigener |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10864265B2 (da) |
| EP (2) | EP3276006A1 (da) |
| CN (1) | CN109923212B (da) |
| DK (1) | DK3491139T3 (da) |
| ES (1) | ES2914238T3 (da) |
| PL (1) | PL3491139T3 (da) |
| PT (1) | PT3491139T (da) |
| WO (1) | WO2018019705A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114107393A (zh) * | 2021-04-07 | 2022-03-01 | 上海劲威生物科技有限公司 | 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6365150B1 (en) * | 1998-05-13 | 2002-04-02 | Genetix Pharmaceuticals, Inc. | Lentiviral packaging cells |
| ATE449858T1 (de) | 1999-10-11 | 2009-12-15 | Pasteur Institut | Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen |
| WO2008103380A2 (en) * | 2007-02-21 | 2008-08-28 | Fox Chase Cancer Center | Hepatitis b virus compositions and methods of use |
| US9393299B2 (en) * | 2009-08-07 | 2016-07-19 | Transgene S.A. | Composition for treating HBV infection |
| CN102038948B (zh) * | 2009-10-10 | 2013-04-10 | 复旦大学 | 一种控制乙型肝炎病毒持续性感染的疫苗 |
| EP2666477A1 (en) * | 2012-05-23 | 2013-11-27 | Theravectys | Lentiviral vectors containing an MHC class I promoter |
| MA34956B1 (fr) * | 2011-02-12 | 2014-03-01 | Globeimmune Inc | Therapeutique a base de levure pour infection chronique par l'hepatite b |
| CN106459998A (zh) * | 2014-05-16 | 2017-02-22 | 耶鲁大学 | 预防或治疗慢性乙型肝炎病毒(hbv)感染的基于病毒样囊泡(vlv)的疫苗 |
| WO2016120492A1 (en) * | 2015-02-01 | 2016-08-04 | Theravectys | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens |
-
2016
- 2016-07-27 EP EP16305976.9A patent/EP3276006A1/en not_active Withdrawn
-
2017
- 2017-07-20 WO PCT/EP2017/068412 patent/WO2018019705A1/en unknown
- 2017-07-20 PL PL17749145.3T patent/PL3491139T3/pl unknown
- 2017-07-20 US US16/320,772 patent/US10864265B2/en active Active
- 2017-07-20 CN CN201780046919.6A patent/CN109923212B/zh active Active
- 2017-07-20 DK DK17749145.3T patent/DK3491139T3/da active
- 2017-07-20 ES ES17749145T patent/ES2914238T3/es active Active
- 2017-07-20 PT PT177491453T patent/PT3491139T/pt unknown
- 2017-07-20 EP EP17749145.3A patent/EP3491139B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3491139T (pt) | 2022-06-20 |
| ES2914238T3 (es) | 2022-06-08 |
| EP3491139A1 (en) | 2019-06-05 |
| CN109923212A (zh) | 2019-06-21 |
| US20190160166A1 (en) | 2019-05-30 |
| EP3491139B1 (en) | 2022-04-06 |
| EP3276006A1 (en) | 2018-01-31 |
| WO2018019705A1 (en) | 2018-02-01 |
| US10864265B2 (en) | 2020-12-15 |
| PL3491139T3 (pl) | 2022-08-16 |
| CN109923212B (zh) | 2023-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3218489T3 (da) | Hepatitis-B-virus (HBV)-IRNA-sammensætninger og fremgangsmåder til anvendelse deraf | |
| IL264575A (en) | RNA materials for hepatitis b virus infection | |
| DK3400291T3 (da) | Manipuleret virus | |
| DK3366295T3 (da) | Fremgangsmåder til behandling af filoviridae virusinfektioner | |
| DK3349580T3 (da) | Hepatitis b kerneproteinmodulatorer | |
| DK3390441T3 (da) | Antistoffer til neutralisering af human immundefekt virus | |
| DK3356390T3 (da) | Fremgangsmåder og sammensætninger til virusvektorer, der undgår antistoffer | |
| DK3359564T3 (da) | Antistoffer til potent neutralisering af hepatitis B-virus og anvendelser deraf | |
| DK3552615T3 (da) | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer | |
| DK3707723T3 (da) | Teknikker til indeksering af nukleinsyrer | |
| DK3377618T3 (da) | Buffere til stabilisering af lentivirus-præparater | |
| DK3083970T3 (da) | Fremgangsmåde til oprensning af kappebærende virusser eller virale vektorer | |
| DK3116316T3 (da) | Allosteriske modulatorer af hepatitis b-kerneprotein | |
| DK3563156T3 (da) | Fremgangsmåde til separering af biomolekyler | |
| DK3684377T3 (da) | Fremgangsmåder til behandling af hepatitis-b-infektion | |
| DK3559484T3 (da) | System til sammenføjning eller forstærkning af komponenter | |
| DK3526323T5 (da) | Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet | |
| DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
| DK3515990T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
| DK3393468T3 (da) | Fremgangsmåder til behandling af en immundefektsygdom | |
| DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
| SG10201913958QA (en) | Modulation of hepatitis b virus replication | |
| DK3113795T3 (da) | Rekombinante virale isfahan-vektorer | |
| DK3370723T3 (da) | Behandling af hepatitis delta-virusinfektion | |
| DK3587231T3 (da) | Forbedringer af en elliptisk foldbar cykel |